Apogee Therapeutics, Inc.
APGE
Rangering i aksjer
#2358
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its... Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Aksjekurs
$135.07
Sist synkronisert: 2026-09-04
Markedsverdi
$8.36B
Endring (1 dag)
0.00%
Endring (1 år)
144.91%
Land
US
Handel Apogee Therapeutics, Inc. (APGE)
Kategori
Healthcare
EPS for Apogee Therapeutics, Inc. (APGE)
EPS per June 2026 TTM: $-4.34
Ifølge de siste økonomiske rapportene og aksjekursen til Apogee Therapeutics, Inc. er selskapets nåværende EPS (TTM) $-4.34. Ved slutten av 2023 hadde selskapet en EPS på $-1.66, en økning sammenlignet med EPS-en i 2022 som var $-0.79.
EPS-historikk for Apogee Therapeutics, Inc. fra 2022 til 2026
EPS ved slutten av hvert år
| År | EPS | Endre |
|---|---|---|
| 2026 (TTM) | $-4.34 | 31.52% |
| 2024 | $-3.30 | 98.80% |
| 2023 | $-1.66 | 110.13% |
| 2022 | $-0.79 | 0.00% |
EPS for lignende selskaper eller konkurrenter
| Selskap | EPS | EPS-forskjell | Land |
|---|---|---|---|
| $17.32 | -499.08% |
US
|
|
| $-7.98 | 83.87% |
US
|
|
| $-5.29 | 21.89% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -739.17% |
NL
|
